CA-125 in benign and malignant diseases involving coelomic epithelium

F. Pavesi, M. Lotzniker, L. Marbello, P. Garbagnoli, M. Franchi, R. Moratti

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The presence of CA-125 (cut-off 35 U/ml) was assessed in serum from 263 neoplastic and 65 non neoplastic patients and in the pleural or ascitic fluid from 84 of them (49 neoplastic and 35 non neoplastic). Tumors (including mesotheliomas, mucinous and non-mucinous ovarian carcinomas, primitive and metastatic cancers of lung and liver and of the digestive tract) were staged according to TNM and FIGO classification and the tumors with peritoneal or pleural effusion considered apart. Non malignant patients had liver cirrhosis, lung inflammation and effusions due to heart failure. CA-125 was positive in most of the sera from patients with ovarian cancer and benign and malignant serous involvement; high concentrations were found in all examined effusions. The relationship between development of serous effusion and the increasing level of serum CA-125 could explain the abnormal serum concentrations found in diseases with peritoneal or pleural involvement. This could also explain the increased levels of CA-125 and ovarian carcinoma (including mucinous) progression which may extend resulting in peritoneal localization. Elevation of serum CA-125 may be expected in patients with all types of diseases affecting peritoneum and pleura and this marker may be used in the follow-up of epithelial ovarian carcinomas as well as of tumors involving coelomic epithelium.

Original languageEnglish
Pages (from-to)49-57
Number of pages9
JournalJournal of Tumor Marker Oncology
Volume3
Issue number1
Publication statusPublished - 1988

Fingerprint

Epithelium
Serum
Ascitic Fluid
Peritoneal Diseases
Pleural Diseases
Carcinoma
Mucinous Adenocarcinoma
Neoplasms
Pleura
Neoplasm Staging
Peritoneum
Mesothelioma
Pleural Effusion
Liver Neoplasms
Liver Cirrhosis
Ovarian Neoplasms
Gastrointestinal Tract
Lung Neoplasms
Pneumonia
Heart Failure

ASJC Scopus subject areas

  • Cancer Research

Cite this

Pavesi, F., Lotzniker, M., Marbello, L., Garbagnoli, P., Franchi, M., & Moratti, R. (1988). CA-125 in benign and malignant diseases involving coelomic epithelium. Journal of Tumor Marker Oncology, 3(1), 49-57.

CA-125 in benign and malignant diseases involving coelomic epithelium. / Pavesi, F.; Lotzniker, M.; Marbello, L.; Garbagnoli, P.; Franchi, M.; Moratti, R.

In: Journal of Tumor Marker Oncology, Vol. 3, No. 1, 1988, p. 49-57.

Research output: Contribution to journalArticle

Pavesi, F, Lotzniker, M, Marbello, L, Garbagnoli, P, Franchi, M & Moratti, R 1988, 'CA-125 in benign and malignant diseases involving coelomic epithelium', Journal of Tumor Marker Oncology, vol. 3, no. 1, pp. 49-57.
Pavesi F, Lotzniker M, Marbello L, Garbagnoli P, Franchi M, Moratti R. CA-125 in benign and malignant diseases involving coelomic epithelium. Journal of Tumor Marker Oncology. 1988;3(1):49-57.
Pavesi, F. ; Lotzniker, M. ; Marbello, L. ; Garbagnoli, P. ; Franchi, M. ; Moratti, R. / CA-125 in benign and malignant diseases involving coelomic epithelium. In: Journal of Tumor Marker Oncology. 1988 ; Vol. 3, No. 1. pp. 49-57.
@article{670fd6d6bb4d414385d29db41cc5facc,
title = "CA-125 in benign and malignant diseases involving coelomic epithelium",
abstract = "The presence of CA-125 (cut-off 35 U/ml) was assessed in serum from 263 neoplastic and 65 non neoplastic patients and in the pleural or ascitic fluid from 84 of them (49 neoplastic and 35 non neoplastic). Tumors (including mesotheliomas, mucinous and non-mucinous ovarian carcinomas, primitive and metastatic cancers of lung and liver and of the digestive tract) were staged according to TNM and FIGO classification and the tumors with peritoneal or pleural effusion considered apart. Non malignant patients had liver cirrhosis, lung inflammation and effusions due to heart failure. CA-125 was positive in most of the sera from patients with ovarian cancer and benign and malignant serous involvement; high concentrations were found in all examined effusions. The relationship between development of serous effusion and the increasing level of serum CA-125 could explain the abnormal serum concentrations found in diseases with peritoneal or pleural involvement. This could also explain the increased levels of CA-125 and ovarian carcinoma (including mucinous) progression which may extend resulting in peritoneal localization. Elevation of serum CA-125 may be expected in patients with all types of diseases affecting peritoneum and pleura and this marker may be used in the follow-up of epithelial ovarian carcinomas as well as of tumors involving coelomic epithelium.",
author = "F. Pavesi and M. Lotzniker and L. Marbello and P. Garbagnoli and M. Franchi and R. Moratti",
year = "1988",
language = "English",
volume = "3",
pages = "49--57",
journal = "Journal of Tumor Marker Oncology",
issn = "0886-3849",
publisher = "International Academy of Tumor Marker Oncology",
number = "1",

}

TY - JOUR

T1 - CA-125 in benign and malignant diseases involving coelomic epithelium

AU - Pavesi, F.

AU - Lotzniker, M.

AU - Marbello, L.

AU - Garbagnoli, P.

AU - Franchi, M.

AU - Moratti, R.

PY - 1988

Y1 - 1988

N2 - The presence of CA-125 (cut-off 35 U/ml) was assessed in serum from 263 neoplastic and 65 non neoplastic patients and in the pleural or ascitic fluid from 84 of them (49 neoplastic and 35 non neoplastic). Tumors (including mesotheliomas, mucinous and non-mucinous ovarian carcinomas, primitive and metastatic cancers of lung and liver and of the digestive tract) were staged according to TNM and FIGO classification and the tumors with peritoneal or pleural effusion considered apart. Non malignant patients had liver cirrhosis, lung inflammation and effusions due to heart failure. CA-125 was positive in most of the sera from patients with ovarian cancer and benign and malignant serous involvement; high concentrations were found in all examined effusions. The relationship between development of serous effusion and the increasing level of serum CA-125 could explain the abnormal serum concentrations found in diseases with peritoneal or pleural involvement. This could also explain the increased levels of CA-125 and ovarian carcinoma (including mucinous) progression which may extend resulting in peritoneal localization. Elevation of serum CA-125 may be expected in patients with all types of diseases affecting peritoneum and pleura and this marker may be used in the follow-up of epithelial ovarian carcinomas as well as of tumors involving coelomic epithelium.

AB - The presence of CA-125 (cut-off 35 U/ml) was assessed in serum from 263 neoplastic and 65 non neoplastic patients and in the pleural or ascitic fluid from 84 of them (49 neoplastic and 35 non neoplastic). Tumors (including mesotheliomas, mucinous and non-mucinous ovarian carcinomas, primitive and metastatic cancers of lung and liver and of the digestive tract) were staged according to TNM and FIGO classification and the tumors with peritoneal or pleural effusion considered apart. Non malignant patients had liver cirrhosis, lung inflammation and effusions due to heart failure. CA-125 was positive in most of the sera from patients with ovarian cancer and benign and malignant serous involvement; high concentrations were found in all examined effusions. The relationship between development of serous effusion and the increasing level of serum CA-125 could explain the abnormal serum concentrations found in diseases with peritoneal or pleural involvement. This could also explain the increased levels of CA-125 and ovarian carcinoma (including mucinous) progression which may extend resulting in peritoneal localization. Elevation of serum CA-125 may be expected in patients with all types of diseases affecting peritoneum and pleura and this marker may be used in the follow-up of epithelial ovarian carcinomas as well as of tumors involving coelomic epithelium.

UR - http://www.scopus.com/inward/record.url?scp=0023910558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023910558&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0023910558

VL - 3

SP - 49

EP - 57

JO - Journal of Tumor Marker Oncology

JF - Journal of Tumor Marker Oncology

SN - 0886-3849

IS - 1

ER -